中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
7期
966-968
,共3页
李青%李明川%王永兴%姜永光
李青%李明川%王永興%薑永光
리청%리명천%왕영흥%강영광
前列腺肿瘤%近距离放疗%内分泌治疗%比卡鲁胺%戈舍瑞林
前列腺腫瘤%近距離放療%內分泌治療%比卡魯胺%戈捨瑞林
전렬선종류%근거리방료%내분비치료%비잡로알%과사서림
Prostate cancer%Brachytherapy%Endocrine therapy%Bicalutamide%Goserelin
目的 探讨近距离放疗联合比卡鲁胺150 mg单药治疗前列腺癌的可行性.方法 将符合入选标准的71例前列腺癌患者按随机数字表分为单药组(34例)和联合药物组(37例).接受近距离放疗后,单药组采用比卡鲁胺150 mg单药内分泌治疗；联合药物组接受戈舍瑞林3.6 mg+比卡鲁胺50 mg内分泌治疗.分别观察治疗前后的前列腺特异抗原(PSA)变化情况,第一阶段用药时间,严密记录治疗过程中的不良事件,并进行安全性评价.结果 单药组有2例、联合药物组有1例在治疗1年后血清PSA不能下降到术前的50％予以剔除.2组患者在接受近距离放疗联合药物治疗1个月后,PSA值均出现了“断崖式”的下降.在随后的治疗中,联合药物组和单药组不良反应发生率差异无统计学意义[(41.7％(15/36)比31.3％(10/32),P=0.37].PSA抑制率二者差异有统计学意义[(96±24)％比(98±24)％,P＜0.01),但对于低危患者,二者差异无统计学意义[(98±24)％比(100±25)％,P＞0.05).联合药物组用药时间短于单药组[(8.1±2.0)个月比(9.5±2.5)个月,P＜0.01],但对于低危患者,二者之间差异无统计学意义(P＞0.05).结论 前列腺癌的近距离放疗联合戈舍瑞林3.6 mg+比卡鲁胺50 mg双药内分泌治疗效果较好,而对于低危患者,采用比卡鲁胺150 mg单药联合近距离放疗的方案,亦能达到同样效果.
目的 探討近距離放療聯閤比卡魯胺150 mg單藥治療前列腺癌的可行性.方法 將符閤入選標準的71例前列腺癌患者按隨機數字錶分為單藥組(34例)和聯閤藥物組(37例).接受近距離放療後,單藥組採用比卡魯胺150 mg單藥內分泌治療；聯閤藥物組接受戈捨瑞林3.6 mg+比卡魯胺50 mg內分泌治療.分彆觀察治療前後的前列腺特異抗原(PSA)變化情況,第一階段用藥時間,嚴密記錄治療過程中的不良事件,併進行安全性評價.結果 單藥組有2例、聯閤藥物組有1例在治療1年後血清PSA不能下降到術前的50％予以剔除.2組患者在接受近距離放療聯閤藥物治療1箇月後,PSA值均齣現瞭“斷崖式”的下降.在隨後的治療中,聯閤藥物組和單藥組不良反應髮生率差異無統計學意義[(41.7％(15/36)比31.3％(10/32),P=0.37].PSA抑製率二者差異有統計學意義[(96±24)％比(98±24)％,P＜0.01),但對于低危患者,二者差異無統計學意義[(98±24)％比(100±25)％,P＞0.05).聯閤藥物組用藥時間短于單藥組[(8.1±2.0)箇月比(9.5±2.5)箇月,P＜0.01],但對于低危患者,二者之間差異無統計學意義(P＞0.05).結論 前列腺癌的近距離放療聯閤戈捨瑞林3.6 mg+比卡魯胺50 mg雙藥內分泌治療效果較好,而對于低危患者,採用比卡魯胺150 mg單藥聯閤近距離放療的方案,亦能達到同樣效果.
목적 탐토근거리방료연합비잡로알150 mg단약치료전렬선암적가행성.방법 장부합입선표준적71례전렬선암환자안수궤수자표분위단약조(34례)화연합약물조(37례).접수근거리방료후,단약조채용비잡로알150 mg단약내분비치료；연합약물조접수과사서림3.6 mg+비잡로알50 mg내분비치료.분별관찰치료전후적전렬선특이항원(PSA)변화정황,제일계단용약시간,엄밀기록치료과정중적불량사건,병진행안전성평개.결과 단약조유2례、연합약물조유1례재치료1년후혈청PSA불능하강도술전적50％여이척제.2조환자재접수근거리방료연합약물치료1개월후,PSA치균출현료“단애식”적하강.재수후적치료중,연합약물조화단약조불량반응발생솔차이무통계학의의[(41.7％(15/36)비31.3％(10/32),P=0.37].PSA억제솔이자차이유통계학의의[(96±24)％비(98±24)％,P＜0.01),단대우저위환자,이자차이무통계학의의[(98±24)％비(100±25)％,P＞0.05).연합약물조용약시간단우단약조[(8.1±2.0)개월비(9.5±2.5)개월,P＜0.01],단대우저위환자,이자지간차이무통계학의의(P＞0.05).결론 전렬선암적근거리방료연합과사서림3.6 mg+비잡로알50 mg쌍약내분비치료효과교호,이대우저위환자,채용비잡로알150 mg단약연합근거리방료적방안,역능체도동양효과.
Objective To assess the feasibility of brachytherapy combined with bicalutamide 150 mg monotherapy for the treatment of prostate cancer.Methods All 71 patients who met the inclusion criteria participated in a randomized controlled study.68 patients with prostate cancer were randomly divided into two groups after brachytherapy.32 cases were treated with bicalutamide 150 mg monotherapy; other 36 patients received goserelin 3.6 mg combined with bicalutamide 50 mg.Prostate specific antigen (PSA) changes were observed before and after treatment and during the first stage of treatment; adverse events were recorded and security was evaluated.Chi-square test and t-test were used for statistical analysis.Results Demographic characteristics and baseline data of the 2 groups of patients were similar.After one month of brachytherapy combined with drug treatment,PSA values showed a “cliff-style” decline; during the subsequent treatment,the incidence of side effects was similiar (41.7％ vs 31.3 ％,P =0.37) while PSA changes showed statistically significant difference [(96 ± 24) ％ vs (98 ± 24) ％,P =0.009],but for low-risk patients,there was no difference [(98 ± 24) ％ vs (100 ± 25) ％,P ＞ 0.05].Conclusion For prostate cancer patients,brachytherapy combined with hormonal therapy,goserelin 3.6 mg+ bicalutamide 50 mg are recommended for low-risk cases; brachytherapy with bicalutamide 150 mg monotherapy can also achieve the same effect.
